Advertise on podcast: Diabetes Insights - Breakthroughs and Innovators

How did decades of research into gut hormones lead to GLP-1-based treatments for type 2 diabetes and obesity? In this EASD TV conversation, host Vivienne Parry speaks with Prof. Jens Juul Holst, recipient of the 2nd Global Impact Prize, about the early discoveries behind GLP-1, the development of effective therapies and their wider metabolic and cardiovascular effects. He also discusses global access and affordability, the challenges of counterfeit medicines, and why fundamental research continues to shape the future of diabetes treatment.

In this EASD TV interview, Prof. Zachary Gerhart-Hines (Novo Nordisk Foundation Center for Basic Metabolic Research), 61st EASD Minkowski Prize recipient, discusses research into the neurokinin-2 receptor (NK2R) and its potential to change how we approach weight management and metabolic health. Where many existing treatments focus on reducing food intake, NK2R activation could offer a complementary strategy by increasing energy expenditure, influencing appetite and improving insulin sensitivity. The conversation explores why the quality of weight loss matters and why this could be important for older adults. Prof. Gerhart-Hines also explains how the pathway’s unexpected connections between fat tissue, the brain and the gut have shaped the research, and how potential NK2R-based therapies could eventually complement treatments such as GLP-1 receptor agonists and amylin-based therapies.

How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes? Prof. Kei Sakamoto, recipient of the 12th EASD - Novo Nordisk Foundation Prize for Excellence, speaks to EASD TV host Vivienne Parry about the molecular mechanisms connecting exercise, energy regulation and insulin signalling. He explains the role of LKB1 and AMPK, explores the potential and limitations of targeting these pathways therapeutically. The conversation also explores the complexity of diabetes, the importance of targeting specific molecular pathways and tissues and why fundamental research is essential for developing future treatments.

Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease. From the early recognition of type 1 diabetes as an autoimmune disease to pioneering birth cohort studies, early detection and screening, Prof. Ziegler discusses the discoveries that have shaped the field and the emergence of treatments that can delay disease progression. She also discusses what remains to be understood about disease progression, possible environmental modifiers and the future of type 1 diabetes prevention.

The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia. Drawing on two years of multidisciplinary work, the guideline was developed by clinicians, methodologists, psychologists and people with lived experience. Prof. Jane Speight, Prof. Richard Holt and patient-advocate Michelle Law describe what diabetes distress is (the emotional burden tied to daily self-management) and why routine assessment and supportive care must become part of standard practice. The conversation explores the definition of diabetes distress, evidence gaps, assessment tools, psychological interventions and how healthcare systems can better support people living with diabetes. The guideline was developed using internationally recognised standards, with people with lived experience involved throughout the process.

How can people living with diabetes help shape the future of diabetes care? In this episode of the EASD Podcast, recorded at the EASD Annual Meeting, Vivienne Parry is joined by Bastian Hauck and Renza Scibilia from the Diabetes Online Community (Dedoc). Together, they discuss some of the key issues facing people living with type 1 diabetes today, including emerging off-label therapies such as GLP-1 receptor agonists, advances in continuous glucose monitoring, responsible use of health data, and the ongoing effort to end diabetes stigma. The conversation highlights why people with lived experience must be involved at every stage of research, innovation and policy-making, ensuring that new therapies and technologies truly meet the needs of those they are designed to support. Throughout the discussion, one message stands above all: "Nothing about us without us." It is a principle that Bastian championed throughout his work and one that continues to guide patient advocacy across the global diabetes community. This episode is dedicated to the memory of our friend and colleague, Bastian Hauck, whose passion for patient advocacy and unwavering commitment to ensuring that people living with diabetes always had a voice continue to inspire us.

In this episode, Dr Jeroen van der Velde explores one of the most common questions in lifestyle medicine: does the time of day you exercise make a difference? Drawing on the latest research presented at the EASD Annual Meeting, he discusses how exercise timing may influence glycaemic control, the role of circadian rhythms in metabolic health, and why later-day exercise appears to offer benefits for people living with or at risk of type 2 diabetes. The conversation also examines chronotypes, shift work, meal timing and the importance of personalised lifestyle advice, while reinforcing the key message that regular physical activity remains the most important goal.

In this episode, Elizabeth Robertson, Director of Research and Clinical at Diabetes UK, and Rachel Connor, Director of Research Partnerships at Breakthrough T1D, discuss why prevention has become one of the biggest topics in type 1 diabetes research. They explore how decades of charity-funded research have led to exciting advances in immunotherapies that can delay the onset of type 1 diabetes, the growing importance of early screening programmes, and the promise of stem cell-derived beta cell therapies. They also explain why collaboration between researchers, charities, healthcare professionals, policymakers and people living with diabetes will be essential to ensure these breakthroughs become accessible treatments that improve lives worldwide.

In this episode, former EASD President Prof. Stefano Del Prato joins host Vivienne Parry to reflect on leading EASD during the unprecedented challenges of the COVID-19 pandemic. He shares how EASD rapidly transformed its Annual Meeting into a successful virtual event, unexpectedly reaching more than 20,000 participants worldwide and strengthening connections with the global diabetes community. The conversation explores how these experiences led to the creation of the EASD Global Council, expanded international collaboration and new initiatives that continue to shape the organisation today. Prof. Del Prato also discusses the enduring value of face-to-face scientific meetings, the importance of bringing researchers together and the innovations that continue to make the EASD Annual Meeting one of the world's leading diabetes conferences.

In this episode, Prof. João Filipe Raposo (Portugal) and Prof. Harald Sourij (Austria) join Vivienne Parry to debate one of the most discussed topics in modern diabetes care: the role of artificial intelligence. The conversation explores how AI is already being used to support diabetes management, including automated insulin delivery systems, continuous glucose monitoring and risk prediction. At the same time, the speakers examine the challenges of translating AI research into everyday clinical practice, highlighting the need for robust evidence, high-quality data and meaningful patient outcomes. They also discuss data privacy, regulation, patient trust and why human expertise and empathy remain central to diabetes care. Discover how AI could shape the future of diabetes management and why careful implementation matters just as much as technological innovation.

In this episode, EASD tv host Vivienne Parry speaks with Prof. Daisuke Yabe (Kyoto University) about the growing global impact of EASD and the importance of international collaboration in diabetes research. Prof. Yabe explains the key differences between diabetes phenotypes in Europe and East Asia, highlighting how obesity, insulin resistance and beta cell dysfunction vary across populations. He discusses how sharing these perspectives is driving better research, stronger international partnerships and improved diabetes care worldwide. The conversation also explores one of the most exciting developments in regenerative medicine: iPS cell-derived islet transplantation. Professor Yabe shares how clinical trials in Japan are addressing donor shortages using induced pluripotent stem cells and discusses the progress being made towards more scalable cell therapies for people living with type 1 diabetes.

In this episode, Prof. Thomas Karagiannis and Dr Francesco Zaccardi take us behind the scenes of clinical guideline development at EASD. As methodologists involved in creating the first EASD clinical guidelines, they explain how rigorous evidence review, transparent processes and careful management of conflicts of interest help ensure recommendations are trustworthy and evidence-based. The discussion explores the newly developed guideline on diabetes distress, upcoming guidance on continuous glucose monitoring in type 2 diabetes, and future recommendations on diabetes prevention. Along the way, Thomas and Francesco highlight the importance of patient involvement, the role of systematic reviews and meta-analyses, and the emerging opportunities for artificial intelligence in guideline development. Join us for an insightful look at the work that transforms scientific evidence into practical recommendations that can shape diabetes care across Europe and beyond.

In this episode, Dame Melanie Davies and Prof. Amanda Adler discuss the development of a new EASD clinical guideline on continuous glucose monitoring (CGM) in people living with type 2 diabetes. As CGM becomes increasingly available, clinicians, researchers, and policymakers are seeking clear evidence-based guidance on its role in diabetes management. The discussion explores why CGM was selected as a priority topic, how guideline questions are developed, the importance of patient involvement, and the rigorous process used to evaluate clinical evidence. The conversation also highlights the broader outcomes that matter to people living with diabetes (including quality of life, confidence and behaviour change) and examines how future recommendations could influence healthcare policy and access to diabetes technology across Europe and beyond.

In this episode, Prof. Eberhard Standl marks an extraordinary milestone - 50 years since attending his first EASD Congress. Looking back on a career spanning five decades, he shares how diabetes care has evolved from the challenges of diabetic ketoacidosis in the 1970s to today's advances in continuous glucose monitoring, hybrid closed-loop systems, immunotherapies, and the potential reversal of type 2 diabetes. Prof. Standl discusses the enduring importance of lifestyle interventions, the value of long-term partnerships between clinicians and people living with diabetes, and emerging research linking diabetes, obesity, metabolism, and cancer. He also reflects on the collaborative spirit of the diabetes research community and the exciting possibilities that lie ahead for both type 1 and type 2 diabetes.

In this episode, Prof. Richard Holt and Prof. Kirsten Nørgaard discuss the updated EASD-ADA Consensus Report on Type 1 Diabetes, a comprehensive update designed to provide timely, evidence-based guidance for healthcare professionals managing type 1 diabetes. They explain how consensus reports differ from formal clinical guidelines, why they remain an important tool for advancing diabetes care, and how the latest update reflects major developments in diabetes technology and clinical practice since the original report was published in 2021. The conversation explores stronger recommendations for continuous glucose monitoring (CGM) and automated insulin delivery systems, as well as new sections covering obesity management, diabetes-related complications, and cardiovascular risk factors. The speakers also discuss how consensus reports can influence healthcare policy, improve access to diabetes technologies, and support more consistent standards of care worldwide. With the report currently open for public consultation, they highlight why feedback from the diabetes community is essential to shaping the final document and ensuring its relevance across diverse healthcare settings.